Precigen, Inc. Working Capital

Working Capital of PGEN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Working Capital growth rates and interactive chart. Working capital, also known as net working capital (NWC), is the difference between a company’s current assets, such as cash, accounts receivable (customers’ unpaid bills) and inventories of raw materials and finished goods, and its current liabilities, such as accounts payable. Net operating working capital is a measure of a company's liquidity and refers to the difference between operating current assets and operating current liabilities. In many cases these calculations are the same and are derived from company cash plus accounts receivable plus inventories, less accounts payable and less accrued expenses. Working capital is a measure of a company's liquidity, operational efficiency and its short-term financial health. If a company has substantial positive working capital, then it should have the potential to invest and grow. If a company's current assets do not exceed its current liabilities, then it may have trouble growing or paying back creditors, or even go bankrupt.

Highlights and Quick Summary

  • Working Capital for the quarter ending September 29, 2021 was $124 Million (a -2.9% decrease compared to previous quarter)
  • Year-over-year quarterly Working Capital increased by 16.18%
  • Annual Working Capital for 2020 was $107 Million (a -4.39% decrease from previous year)
  • Annual Working Capital for 2019 was $112 Million (a -50.1% decrease from previous year)
  • Annual Working Capital for 2018 was $224 Million (a 203.11% increase from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Working Capital of Precigen, Inc.

Most recent Working Capitalof PGEN including historical data for past 10 years.

Interactive Chart of Working Capital of Precigen, Inc.

Precigen, Inc. Working Capital for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $124.1 $127.82 $118.88
2020 $106.82 $120.46 $108.9 $118.75 $106.82
2019 $111.73 $75.38 $131.53 $172.75 $111.73
2018 $223.92 $218.14 $64.57 $110.96 $223.92
2017 $73.87 $91.94 $138.43 $191.02 $73.87
2016 $220.58 $215.7 $250.16 $258.6 $220.58
2015 $247.9 $225.34 $236.73 $190.1 $247.9
2014 $127.29 $142.04 $167.61 $210.72 $127.29
2013 $167.73 $186.52 $116.81 $167.73
2012 $-3.18
2011 $5.38 $5.38

Business Profile of Precigen, Inc.

Sector: Healthcare
Industry: Biotechnology
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Fibrocell Science, Inc.; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Holdings, Inc. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.